secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2026-08-12T20:52:25+00:00
Accession:  0001437749-26-027356
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Q2 net loss narrows to $2.4M; cash $19.9M; brilaroxazine patent extension pursued
--------------------------------------------------------------------------------

- Net loss $2.4M ($0.19/share) for Q2 2026 vs $6.1M ($2.40/share) year ago; per-share reflects 1:20 reverse split.
- Cash and equivalents $19.9M at June 30, 2026 vs $14.4M at Dec 31, 2025.
- Filed US composition-of-matter patent for new brilaroxazine form to extend exclusivity through 2046.
- FDA feedback on using new formulation in RECOVER-2 trial and NDA expected Q4 2026; bioequivalence study planned Q4 2026.
- Patient enrollment in RECOVER-2 Phase 3 trial expected 1H 2027, subject to additional financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774926027356/0001437749-26-027356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774926027356/rvph20260729_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-027356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer